Patent of Eli-Lilly's Blockbuster Lung Cancer Drug Alimta Upheld
Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.
The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the '209 Patent are invalid.
However, the decision that would preserve the $2.6 billion-a-year drug from generic competition until 2022, could change if generic drug companies appeal the ruling.
Read the complete report here: http://reut.rs/1s2sdUK